HAWKTAIL — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
Envisagenics uses AI-driven analysis of RNA splicing to discover novel drug targets for immuno-oncology and neurodegenerative diseases.
AI & Machine LearningBiotechMedical DevicesNew York, US
Maria Pineda, PhD(CEO & Co-founder)Martin Akerman, PhD(CEO & Co-founder)Martin Akerman(Executive Officer, Director, Promoter)Maria Luisa Pineda(Executive Officer, Director, Promoter)Maria Luisa Pineda, PhD.(Founder)in
Co-investorsDynamk CapitalM12 (Microsoft's Venture Fund)Madrona Venture GroupRed Cell IncubationDolby Family VenturesThird Kind Venture Capital
Teiko provides CLIA-validated high-dimensional cytometry services—including spectral flow and mass cytometry panels, blood preservation kits, gating, and a data analysis dashboard—for immune cell profiling in clinical trials.
BiotechDigital HealthHealthtechSalt Lake City, US
Ramji Srinivasan(Executive Officer, Director)inMatt(Co-founder)inMatthew Spitzer(Director)
BoardVictor Wang(Director)in
Co-investorsCivilization Ventures Management, LlcHOF CapitalTau VenturesTwine VenturesWestern Technology Investment
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.